Wait Times Experienced by Lung Cancer Patients in the BC Southern Interior to Obtain Oncologic Care: Exploration of the Intervals from First Abnormal Imaging to Oncologic Treatment

David Van de Vosse, Rezwan Chowdhury, Andrew Boyce, Ross Halperin, David Van de Vosse, Rezwan Chowdhury, Andrew Boyce, Ross Halperin

Abstract

Background: Lung cancer is associated with rapid disease progression, which can significantly progress over a duration of four to eight weeks. This study examines the time interval lung cancer patients from the interior of British Columbia (BC) experience while undergoing diagnostic evaluation, biopsy, staging, and preparation for treatment.

Methods: A chart review of lung cancer patients (n=231) referred to the BC Cancer Agency Centre for the Southern Interior between January 1, 2010 and December 31, 2011 was performed. Time zero was defined as the date of the first abnormal chest imaging. Time intervals, expressed as median averages, to specialist consult, biopsy, oncologic referral, initial oncology consultation, and commencement of oncologic treatment were obtained.

Results: The median time interval from first abnormal chest imaging to a specialist consultation was 18 days (interquartile range, IQR, 7-36). An additional nine days elapsed prior to biopsy in the form of bronchoscopy, CT-guided biopsy, or sputum cytology (median; IQR, 3-21); if lobectomy was required, 18 days elapsed (median; IQR, 9-28). Eight days were required for pathologic diagnosis and subsequent referral to the cancer centre (median; IQR, 3-16.5). Once referral was received, 10 days elapsed prior to consultation with either a medical or radiation oncologist (median, IQR 5-18). Finally, eight days was required for initiation of radiation and/or chemotherapy (median; IQR, 1-15). The median wait time from detection of lung cancer on imaging to oncologic treatment in the form of radiation and/or chemotherapy was 65.5 days (IQR, 41.5-104.3).

Interpretation: Patients in the BC Southern Interior experience considerable delays in accessing lung cancer care. During this time, the disease has the potential to significantly progress and it is possible that a subset of patients may lose their opportunity for curative intent treatment.

Keywords: lung cancer; outcomes; time interval; wait time.

Conflict of interest statement

The authors have declared that no competing interests exist.

References

    1. Canadian Partnership Against Cancer. Canadian Partnership Against Cancer. Toronto, Canada: [Apr;2015 ]. 2012. The 2012 cancer system performance report; pp. 1–174.
    1. Howlader N, Noone AM, Karachi M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA. National Cancer Institute. Bethesda, Maryland: [Apr;2015 ]. 2013. SEER Cancer Statistics Review, 1975-2011.
    1. Cancer survival in Europe 1999-2007 by country and age:results of WUROCARE-5, a population-based study. De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, Trama A, Visser O, Brenner H, Ardanaz E, Bielska-Lasota M, Engholm G, Nennecke A, Siesling S, Berrino F, Capocaccia R; EUROCARE-5 Working Group. Lancet Oncology. 2014;15:23–34.
    1. British Columbia Cancer Agency. British Columbia Cancer Agency: facts and figures, cancer surveillance and outcomes, population oncology. Vancouver, BC: British Columbia Cancer Agency; [Aug;2015 ]. 2012. Statistics by cancer type: Lung; pp. 1–2.
    1. Clinical features of 5,628 primary lung cancer patients: Experience at mayo clinic from 1997 to 2003. Yang P, Allen MS, Aubry MC, Wampfler JA, Marks RS, Edell ES, Thibodeau S, Adjei AA, Jett J, Deschamps C. Chest. 2005;128:452–462.
    1. CT findings of early-stage small cell lung cancer in a low-dose CT screening programme. Sone S, Nakayama T, Honda T, Tsushima K, Li F, Haniuda M, Takahashi Y, Hanaoka T, Takayama F, Koizumi T, Kubo K, Yamanda T, Kondo R, Fushimi H, Suzuki T. Lung Cancer. 2007;56:207–215.
    1. Tumor doubling time and prognosis in lung cancer patients: evaluation from chest films and clinical follow-up study. Japanese Lung Cancer Screening Research Group. Arai T, Kuroishi T, Saito Y, Kurita Y, Naruke T, Kaneko M. Jpn J Clin Oncol. 1994;24:199–204.
    1. Lung cancer treatment waiting times and tumour growth. O'Rourke N, Edwards R. Clin Oncol (R Coll Radiol) 2000;12:141–144.
    1. Time from finding abnormality on mass-screening to final diagnosis of lung cancer. Kanashiki M, Satoh H, Ishikawa H, Yamashita YT, Ohtsuka M, Sekizawa K. Oncol Rep. 2003;10:649–652.
    1. Effect of preoperative delay on prognosis for patients with early stage non-small cell lung cancer. Quarterman RL, McMillan A, Ratcliffe MB, Block MI. J Thorac Cardiovasc Surg. 2003;125:108–113.
    1. Demographic treatment, and survival patterns for native hawaiians with lung cancer treated at a community medical center from 1995 to 2001. Liu DM, Kwee SA. Pac Health Dialog. 2004;11:139–145.
    1. Impact of a multidisciplinary thoracic oncology clinic on the timeliness of care. Riedel RF, Wang X, McCormack M, Toloza E, Montana GS, Schreiber G, Kelley MJ. J Thorac Oncol. 2006;1:692–696.
    1. Pathways to the diagnosis of lung cancer in the UK: A cohort study. Barrett J, Hamilton W. BMC Fam Pract. 2008;9:31.
    1. Timeliness of care in veterans with non-small cell lung cancer. Gould MK, Ghaus SJ, Olsson JK, Schultz EM. Chest. 2008;133:1167–1173.
    1. Auditing the diagnosis of cancer in primary care: The experience in scotland. Baughan P, O'Neill B, Fletcher E. Br J Cancer. 2009;3:87–91.
    1. Hospital characteristics associated with timeliness of care in veterans with lung cancer. Schultz EM, Powell AA, McMillan A, Olsson JK, Enderle MA, Graham BA, Ordin DL, Gould MK. Am J Respir Crit Care Med. 2009;1:595–600.
    1. Lung cancer diagnostic and treatment intervals in the united states: A health care disparity? Yorio JT, Xie Y, Yan J, Gerber DE. J Thorac Oncol. 2009;4:1322–1330.
    1. UK waiting time targets in lung cancer treatment: are they achievable? Results of a prospective tracking study. Devbhandari MP, Soon SY, Quennell P, Barber P, Krysiak P, Shah R, Jones MT. J Cardiothorac Surg. 2007;2:5.
    1. Are we achieving the current waiting time targets in lung cancer treatment? Result of a prospective study from a large United kingdom teaching hospital. Devbhandari MP, Bittar MN, Quennell P, Barber P, Krysiak P, Shah R, Jones MT. J Thorac Oncol. 2007;2:590–592.
    1. Small cell lung cancer: Time to diagnosis and treatment. Haque N, Raza A, McGoey R, Boulmay B, Diethelm L, Kantrow S. South Med J. 2012;105:418–423.
    1. Time to treat: A system redesign focusing on decreasing the time from suspicion of lung cancer to diagnosis. Lo DS, Zeldin RA, Skrastins R, Fraser IM, Newman H, Monavvari A, Ung YC, Joseph H, Downton T, Maxwell L, Meharchand J. J Thorac Oncol. 2007;2:1001–1006.
    1. Analysis of wait times and costs during the peri-diagnostic period for non-small cell lung cancer. Cheung WY, Butler JR, Kliewer EV, Demers AA, Musto G, Welch S, Sivananthan G, Navaratnam S. Lung Cancer. 2011;72:125–131.
    1. Delays in the diagnosis of lung cancer. Ellis PM, Vandermeer R. J Thorac Dis. 2011;3:183–188.
    1. Wait times in diagnostic evaluation and treatment for patients with stage III non-small cell lung cancer in British Columbia. Wai ES, Mackinnon M, Hooker R, Moccia P, Perry KR, Truong PT. Am J Clin Oncol. 2012;35:373–377.
    1. Health Health, Interior Interior. Kelowna, Canada: [Sep;2014 ]. 2014. Interior Health quick facts: 2014.
    1. The World Bank, Data: Land area (sq. km) [Sep;2014 ];The World Bank. [Internet]. Washington. km. 2013 [cited:2014.
    1. Organization for Economic Cooperation and Development. Organization for Economic Cooperation and Development. Paris, France: 2013. Health at a glance 2013: OECD indicators.
    1. Killing time: The consequences of delays in radiotherapy. Mackillop WJ. Radiother Oncol. 2007;84:1–4.
    1. Canadian Medical Protection Agency. Canadian Medical Protection Agency. Ottawa, Canada: [Aug;2015 ]. 2010. Lung cancer-the challenge of a timely diagnosis; p. 1.
    1. Delays in the diagnosis and treatment of lung cancer. Salomaa ER, Sallinen S, Hiekkanen H, Liippo K. Chest. 2005;128:2282–2288.
    1. Treatment delays in non-small cell lung cancer and their prognostic implications. Diaconescu R, Lafond C, Whittom R. J Thorac Oncol. 2011;6:1254–1259.
    1. Effect of delays on prognosis in patients with non-small cell lung cancer. Myrdal G, Lambe M, Hillerdal G, Lamberg K, Agustsson T, Ståhle E. Thorax. 2004;59:45–49.
    1. Reifel J. Quality of Care for Oncologic Conditions and HIV: A Review of the Literature and Quality Indicators. London, UK: RAND Corporation; 2000. Lung cancer; pp. 133–172.
    1. Del Giudice L, Young S, Vella E, Ash M, Bansal P, Robinson A, Skrastins R, Ung Y, Zeldin R, Levitt C. Program in Evidence-based Care. Vol. 24. Toronto, Ontario, Canada: Cancer Care Ontario; 2011. Referral of suspected lung cancer by family physicians and other primary care providers; p. 2.
    1. Cancer Care Ontario: Systemic treatment wait times. [Sep;2014 ];Cancer Care Ontario [Internet]. Toronto, Canada Canada. 2014
    1. Patient's and doctors' delays in the diagnosis of chest tumors. Koyi H, Hillerdal G, Brandén E. Lung Cancer. 2002;35:53–57.
    1. Redesign of thoracic surgical services within a cancer network-using an oncology focus to inform change. Leary A, Corrigan P. Eur J Oncol Nurs. 2005;9:74–78.
    1. The pathway study: results of a pilot feasibility study in patients suspected of having lung carcinoma investigated in a conventional chest clinic setting compared to a centralised two-stop pathway. Murray PV, O'Brien ME, Sayer R, Cooke N, Knowles G, Miller AC, Varney V, Rowell NP, Padhani AR, MacVicar D, Norton A, Ashley S, Smith IE. Lung Cancer. 2003;42:283–290.
    1. Improving surgical resection rate in lung cancer. Laroche C, Wells F, Coulden R, Stewart S, Goddard M, Lowry E, Price A, Gilligan D. Thorax. 1998;53:445–449.
    1. Lung cancer patients treated faster thanks to Surrey pilot program. Vancouver Sun. [Oct;2014 ];Fayerman Fayerman, P. P. Vancouver Sun (Internet. 2013 Oct:17.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir